Xencor, Inc.
HealthcareNASDAQ:XNCR · NASDAQ Global Market
+$0.24 today
Vol 0.59M · Avg 0.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.5%
avg -9.7%
ROIC
-21.5%
avg -10.0%
ROA
-10.5%
avg -7.2%
Analysis
ROA is currently the strongest return metric at -10.5% versus its period average of -7.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bassil I. Dahiyat | Co-Founder, Chief Executive Officer, President & Director | $1.24M | — | 56 | $546,316.00 | 0.74% |
John R. Desjarlais | Executive Vice President of Research & Chief Scientific Officer | $858,492.00 | — | 62 | $263,831.00 | 0.36% |
Bart Jan Cornelissen | Senior Vice President & Chief Financial Officer | $816,106.00 | — | 48 | $75,898.00 | 0.10% |
Celia E. Eckert | Senior Vice President, General Counsel & Corporate Secretary | $744,189.00 | — | 54 | $76,918.00 | 0.10% |
Mark Osterman | Senior Vice President of Clinical Development (Autoimmune) | — | — | — | — | — |
Dane Vincent Leone | Executive Vice President & Chief Strategy Officer | — | — | — | — | — |
Kirk Rosemark | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | 61 | — | — |
Jennifer Sandoz | Senior VIce President of Human Resources | — | — | — | — | — |
Eric Kowack | Senior Vice President of Program Leadership & Alliance Management | — | — | — | — | — |
Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | — | — | — | $18,905.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
18
$3.65M
Net Sentiment
$3.65M
Net selling
Most Active
Desjarlais John R
4 transactions
1–10 of 18
Analysis
Insiders reported 0 buys worth $0.00 and 18 sells worth $3.65M over the last 12 months. That adds up to net selling of $3.65M. Desjarlais John R was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +42.8% | +20.7% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +42.8% over three years. Forward estimates point to Revenue at +20.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Oculis Holding AG
NASDAQ:OCS
$634.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages XNCR?
Xencor, Inc. (XNCR) lists 10 active executives. The top listed executive is Bart Jan Cornelissen, Senior Vice President & Chief Financial Officer.
Are XNCR insiders buying or selling?
Recent insider activity shows net buying of $59.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.